All articles tagged with #obesity treatment
Obesity specialists say GLP-1 weight-loss medications are becoming a wedding trend, with brides like Laura Patnaude losing about 25 pounds to fit into a gown—though experts note caution, as 40 pounds would be risky for the dress and health.
Lilly has granted compassionate-use access to its obesity drug candidate retatrutide for a single patient, according to STAT’s exclusive reporting; The Readout also covers Pfizer’s lung-cancer trial results and other biotech news.
A large real-world study using NIH All of Us and Fitbit data finds adults starting GLP-1 obesity medications reduce daily steps (5,047→4,487) and MVPA (28→22 minutes), contradicting the assumption that weight loss boosts activity. The decline risks lean muscle loss during rapid weight loss, underscoring the need to pair GLP-1 treatments with structured exercise and resistance training from the start. The analysis, drawn from 1,950 adults with 753 wearing-device users, shows the biggest drops in men and those with joint/muscle pain, while age or cardiovascular history did not shield against the trend; researchers call for integrated behavioral interventions and remote monitoring.
Rapid weight loss from GLP-1 drugs (like Wegovy and Zepbound) can cause “ghost fat,” a brain–body disconnect where people still see themselves as heavier. This phantom fat is more common after fast weight loss and can affect clothing choices, posture, self-esteem, and social behavior. Experts recommend cognitive-behavioral therapy, mindfulness, mirror exposure, and shifting focus from appearance to health to help the brain catch up with the new body.
Some people with eating disorders are using GLP-1 receptor agonists to suppress appetite, prompting alarm from doctors who warn of safety risks and potential to mask underlying conditions; experts call for careful screening and caution around off-label use.
A meta-analysis of 11 cardiovascular outcome trials (over 90,000 patients) finds GLP-1 receptor agonists reduce major cardiovascular events and all-cause mortality by about 13% over an average follow-up of nearly three years, with benefits seen in high-risk groups including those with or without diabetes. While GI side effects (nausea, vomiting) are more common, no significant safety signals like pancreatitis or hypoglycemia emerged. The results suggest these obesity/diabetes drugs may play a broader role in cardiovascular risk reduction and could influence clinical practice and policy.
A new review suggests that for people who don’t respond to GLP-1 weight-loss drugs, adding NB-ER (naltrexone/bupropion) may improve outcomes by reducing hunger and cravings. Genetics may explain nonresponse, and experts say a multi-pronged, personalized approach could help some patients who fail to reach meaningful weight loss with GLP-1 alone.
GLP-1 weight-loss injections can jump-start shedding pounds, but long-term success hinges on lifestyle: regular exercise, better food choices, adequate sleep, and attention to mental health. One patient lost 110 pounds after adding a six-days-a-week workout plan. Doctors warn about potential complications (pancreatitis, gallstones, kidney injury) if dosage is increased too quickly or misused, underscoring the need for medical supervision. Access and cost remain barriers, with limited insurance coverage for obesity and forthcoming Medicare coverage; online suppliers may lack dosing guidance and safety information.
GLP-1 drugs, originally prescribed for type 2 diabetes and obesity, are being explored by healthy individuals in the hope of extending healthspan and possibly lifespan. The evidence is tantalising but not conclusive, and these therapies are far from a proven longevity panacea given uncertainties about long-term effects, risks, and costs.
A Wall Street Journal piece explains that GLP-1 weight-loss medications like Ozempic and Wegovy are intended as lifelong treatments for obesity, not quick lifestyle fixes; studies show most people who stop the drugs regain the lost weight within about 1.5 years, underscoring the need for ongoing treatment and monitoring.
A real-world analysis of 135,000+ patients on GLP-1 therapies (tirzepatide and semaglutide) found weight loss durability after discontinuation. Six months after stopping, about 28% of tirzepatide users regained weight, while 36% kept it off and 36% continued to lose; for semaglutide, ~33% regained, ~32% maintained, and ~35% still lost weight, with a median six‑month change of 0%. The findings suggest durability is possible in routine care and could support a disease-management approach, especially when paired with exercise counseling. Limitations include its observational nature and incomplete accounting for dose and lifestyle factors; results differ from some clinical trial findings and more research is needed to identify who maintains weight loss long-term.
Six new GLP-1–based obesity drugs are racing to challenge Ozempic/Wegovy, including orforglipron (daily pill) with about 10% weight loss at high dose, CagriSema (semaglutide plus amylin) up to 22.7% in a year, VK2735 (GLP-1 + GIP) up to 12% in 13 weeks, MariTide (monthly injection) up to 20% in a year, Retatrutide (GLP-1 + GIP + glucagon) with nearly 30% weight loss over 68 weeks, and Rejuva (gene therapy to boost GLP-1) in early stages; together signaling a broader, more diverse obesity treatment landscape with FDA actions and safety considerations ahead.
A study from the University of Oxford found that stopping GLP-1 receptor agonist drugs like Wegovy and Ozempic leads to rapid weight regain and loss of health benefits within about 1.4 to 1.7 years, highlighting the need for comprehensive, long-term weight management strategies rather than short-term medication use.
Stopping GLP-1 weight-loss drugs causes weight regain four times faster than ending exercise, with most individuals returning to their original weight within 18 months, highlighting the need for long-term management strategies.
Novo Nordisk received FDA approval for Wegovy, the first oral GLP-1 medication for weight loss, which could significantly impact the obesity treatment industry by offering a more convenient option and potentially increasing market share amid rising competition and pricing pressures.